I believe that targeting RNA instead of proteins will revolutionize human medicine. Although profound, the revolution will not be a single stroke. Lot’s of hard work, tons of data and clever scientific thinking is needed to understand and deal with the challenges of realizing the dream. My group’s approach is the meticulous data collection and organization, combined with model building, hypothesis formulation and experimental tests.
At Santaris Pharma I am responsible for informatics. This entails: developing tools for improved oligonucleotide design and improved drug discovery methods as well as general bioinformatics and biostatistics both during the discovery and development phases at Santaris.
A Master in Human Biology and a phd in bioinformatics should provide the background needed to bridge and cross-fertilize between wetlab, computational biology and clinical development.
In the context of COAT I represent the industrial perspective and attempt to extract innovative value from the research we do in COAT.
COAT projects my group is working on:
- Prediction of the hepatotoxic potential of oligonucleotides
- Kinetics models of antisense oligonucleotides (with Lykke Pedersen from Krogh Lab)
- Oligonucleotide protein binding (with Vinther Lab)
- Class effects of LNA oligonucleotides on the mouse transcriptome
- antimiR potency
- Specificity of oligonucleotides (with Vinther Lab)
- LNA-stop-Seq (with Vinther Lab)
LinkedIn | Twitter